Delivery Order SPE2DB22D1106-SPE2DB25FEXP6
- Not listed
- The Defense Logistics Agency awarded a $11,174.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for August 8, 2025. This competitively awarded contract, issued without set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $9,118.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xeomin 50 Unit Vials, with an ultimate completion date of July 11, 2025. This non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- AmerisourceBergen Drug Corp received a $13,409.76 delivery order from the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Xeomin 200 Unit Vials, with completion scheduled for September 3, 2025. This firm fixed price contract award was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Xeomin is a botulinum toxin product used in medical and therapeutic applications, and this...
- The Defense Logistics Agency awarded a delivery order valued at $2,793.70 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic applications. This $10,057.32 firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 22, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Xeomin 50 Unit Vials, with a ceiling value of $3,647.28 and an ultimate completion date of August 29, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on August 8, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order operates...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEXP6Delivery Order
This delivery order, valued at $27,937.00, was awarded on July 14, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Xeomin 200 Unit Vials, with an ultimate completion date of August 4, 2025. The contract carries firm fixed pricing and represents a non-competitive set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle that runs through December 2026. Performance will occur at the vendor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, leverages its comprehensive IDC vehicle to supply a broad range of pharmaceutical products and medical supplies to military healthcare systems and other government agencies, including the Defense Health Agency and U.S. Coast Guard. As a child order under the larger SPE2DX IDC, this delivery order for Xeomin—a botulinum toxin product used in medical and therapeutic applications—exemplifies the company's role in fulfilling specialized pharmaceutical needs within the federal medical supply chain. The DLA's pharmaceutical procurement strategy includes plans for multiple regional contracts under its Pharmaceutical Prime Vendor Global Program Generation V initiative, positioning AmerisourceBergen as one of several strategic vendors supporting military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 7/14/25 |